Devices, methods, compositions and systems for the treatment of aging and age-related disorders
AssigneeGero LLC
InventorsMaksim Nikolaevich KHOLIN, Petr Olegovich FEDICHEV, Olga Andreevna BURMISTROVA, Konstantin Alexandrovich AVKHACHEV, Dmitry Veniaminovich SHISHOV, Andrey Evgenievich TARKHOV
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods, devices, kits, and agents for the treatment of aging and aging related diseases and disorders and related systems and methods.
Claims20
A protein binding device, wherein the protein binding device comprises a housing, wherein the housing defines a lumen and the housing further comprises an inlet port for receiving fluid to the lumen, and an outlet port for releasing fluid from the lumen, wherein the lumen comprises binding elements, wherein the binding elements selectively bind a protein selected from the group consisting of:
- CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB.
A pharmaceutical composition provided as part of an anti-aging treatment or for treating or preventing an age-related disease or disorder comprising an agent configured to bind to, inhibit, or degrade a protein selected from the group consisting of:
- B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB;
- and at least one pharmaceutically acceptable excipient.
A pharmaceutical composition comprising a blood plasma fraction, wherein the blood plasma fraction comprises a negligible amount of a protein selected from the group consisting of CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB.
A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject comprising reducing, inhibiting, or degrading a protein selected from the group consisting of:
- CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB in the blood of the subject.
A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject, comprising administering to the subject a pharmaceutical composition comprising an inhibitor of a protein selected from the group consisting of:
- B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB;
- and at least one pharmaceutically acceptable excipient.
A method of providing an anti-aging treatment or of treating or preventing an age-related disease or disorder of a subject, comprising administering to the subject a pharmaceutical composition comprising a blood plasma fraction, wherein the blood plasma fraction comprises a negligible amount of a protein selected from the group consisting of:
- CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, wherein the negligible amount is between about 0.008 pg/mL and about 15,000 ng/mL.
A kit, comprising:
- a pharmaceutical composition comprising:
- an agent configured to bind to, inhibit, or degrade a protein selected from the group consisting of:
- B2M, CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, wherein the agent is selected from the group consisting of:
- a protein, a polymer, an aptamer, a SOMAmer, a peptide, a virus, a small molecule, a nanoparticle, an antibody, a monoclonal antibody, a polyclonal antibody, a humanized monoclonal antibody, a human monoclonal antibody, a human or humanized polyclonal antibody, an anti-GDF15 human antibody, an anti-FSTL3 human antibody, an anti-BMP4 human antibody, and an anti-FRZB (sFRP3) human antibody, and
- at least one pharmaceutically acceptable excipient;
- and
- an instruction for using the pharmaceutical composition as part of the anti-aging treatment or to treat or prevent an age-related disease or disorder.
A tangible medium comprising a computer program, which, when executed by one or more processors of a computing device, causes the computing device to attribute information regarding a protein binding device, another device, or a therapeutic agent with information about reducing, binding, inhibiting, or degrading at least one protein within the blood of the subject, wherein the protein is selected from the group consisting of:
- CCDC80, CD59, CHRDL1, COL18A1, CST3, DPT, EFEMP1, FAS, FSTL3, GAS1, GDF15, KLK11, MMP7, NBL1, NTN1, POSTN, PTN, RELT, SFRP1, SMOC1, STC1, TNFRSF1A, UNC5C, sFRP-3, TNFRSF1B, CD55, BMP4, and RGMB, and wherein the information about reducing, binding, inhibiting or degrading the protein is associated with an anti-aging treatment.
Dependencies are inferred from the claim text.